María Regina Díaz-Domínguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
María Regina Díaz-Domínguez has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ari Evelyn Castañeda-Ramírez
Carrera de Médico Cirujano, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico
3 shared publications - Héctor Iván Saldívar-Cerón
Carrera de Médico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico
3 shared publications - Axel Eduardo Muciño-Galicia
Carrera de Médico Cirujano, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico
2 shared publications - Jorge Arturo Vargas-Camacho
Carrera de Médico Cirujano, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico
2 shared publications - Paola Briseño-Díaz
Departamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Apartado Postal 07360, Ciudad de México 07360, Mexico
2 shared publications - Sonia Leon-Cabrera
Unidad de Biomedicina (UBIMED), Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico
2 shared publications
Latest Publications
- Open Access
- 11 June 2025
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 93 (2) , 26
Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies
Small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent an innovative advancement in oral therapeutics, addressing key limitations associated with injectable peptide-based incretin therapies. These nonpeptidic agents exert their actions primarily through non-canonical binding orthosteric sites within the GLP-1 receptor transmembrane domain, enabling selective G protein (Gs)-biased signaling with reduced β-arrestin-mediated adverse effects. Orforglipron has notably advanced through Phase 3 clinical development, demonstrating significant reductions in hemoglobin A1c and body weight (up to 7.9%) with favorable tolerability. Conversely, promising candidates such as danuglipron and lotiglipron were discontinued due to hepatotoxicity, underscoring critical safety concerns intrinsic to small-molecule GLP-1RA development. Current clinical candidates, including GSBR-1290, CT-996, and ECC5004, continue to offer substantial potential due to their oral bioavailability, simplified dosing regimens, and favorable gastrointestinal tolerability. Nevertheless, challenges persist regarding hepatic safety, pharmacodynamic variability, and limited long-term outcome data. This review integrates current structural, pharmacological, and clinical evidence, highlights key mechanistic innovations—including biased agonism, covalent binding strategies, and allosteric modulation—and discusses future directions for this rapidly evolving therapeutic class in metabolic disease management.
- 11 June 2025
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 93 (2) , 26
Open AccessOral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies
Small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent an innovative advancement in oral therapeutics, addressing key limitations associated with injectable peptide-based incretin therapies. These nonpeptidic agents exert their actions primarily through non-canonical binding orthosteric sites within the GLP-1 receptor transmembrane domain, enabling selective G protein (Gs)-biased signaling with reduced β-arrestin-mediated adverse effects. Orforglipron has notably advanced through Phase 3 clinical development, demonstrating significant reductions in hemoglobin A1c and body weight (up to 7.9%) with favorable tolerability. Conversely, promising candidates such as danuglipron and lotiglipron were discontinued due to hepatotoxicity, underscoring critical safety concerns intrinsic to small-molecule GLP-1RA development. Current clinical candidates, including GSBR-1290, CT-996, and ECC5004, continue to offer substantial potential due to their oral bioavailability, simplified dosing regimens, and favorable gastrointestinal tolerability. Nevertheless, challenges persist regarding hepatic safety, pharmacodynamic variability, and limited long-term outcome data. This review integrates current structural, pharmacological, and clinical evidence, highlights key mechanistic innovations—including biased agonism, covalent binding strategies, and allosteric modulation—and discusses future directions for this rapidly evolving therapeutic class in metabolic disease management.
- Open Access
- 13 May 2025
- Published by MDPI AG in Preprints.org
Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies
Small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent an innovative advancement in oral therapeutics, addressing key limitations associated with injectable peptide-based incretin therapies. These nonpeptidic agents exert their actions primarily through non-canonical orthosteric sites within the GLP-1 receptor transmembrane domain, enabling selective G protein (Gs)-biased signaling with reduced β-arrestin–mediated adverse effects. Orforglipron has notably advanced through phase 3 clinical development, demonstrating significant reductions in hemoglobin A1c and body weight (up to 7.9%) with favorable tolerability. Conversely, promising candidates such as danuglipron and lotiglipron were discontinued due to hepatotoxicity, underscoring critical safety concerns intrinsic to small-molecule GLP-1RA development. Current clinical candidates, including GSBR-1290, CT-996, and ECC5004, continue to offer substantial potential due to their oral bioavailability, simplified dosing regimens, and favorable gastrointestinal tolerability. Nevertheless, challenges persist regarding hepatic safety, pharmacodynamic variability, and limited long-term outcome data. This review integrates current structural, pharmacological, and clinical evidence, highlights key mechanistic innovations—including biased agonism, covalent binding strategies, and allosteric modulation—and discusses future directions for this rapidly evolving therapeutic class in metabolic disease management.
- 13 May 2025
- Published by MDPI AG in Preprints.org
Open AccessOral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies
Small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent an innovative advancement in oral therapeutics, addressing key limitations associated with injectable peptide-based incretin therapies. These nonpeptidic agents exert their actions primarily through non-canonical orthosteric sites within the GLP-1 receptor transmembrane domain, enabling selective G protein (Gs)-biased signaling with reduced β-arrestin–mediated adverse effects. Orforglipron has notably advanced through phase 3 clinical development, demonstrating significant reductions in hemoglobin A1c and body weight (up to 7.9%) with favorable tolerability. Conversely, promising candidates such as danuglipron and lotiglipron were discontinued due to hepatotoxicity, underscoring critical safety concerns intrinsic to small-molecule GLP-1RA development. Current clinical candidates, including GSBR-1290, CT-996, and ECC5004, continue to offer substantial potential due to their oral bioavailability, simplified dosing regimens, and favorable gastrointestinal tolerability. Nevertheless, challenges persist regarding hepatic safety, pharmacodynamic variability, and limited long-term outcome data. This review integrates current structural, pharmacological, and clinical evidence, highlights key mechanistic innovations—including biased agonism, covalent binding strategies, and allosteric modulation—and discusses future directions for this rapidly evolving therapeutic class in metabolic disease management.
- Open Access
- 22 February 2025
- Published by MDPI AG in Journal of Functional Morphology and Kinesiology
- Vol. 10 (1) , 72
A Novel Metabolic Risk Classification System Incorporating Body Fat, Waist Circumference, and Muscle Strength
Background: As metabolic diseases continue to rise globally, there is a growing need to improve risk assessment strategies beyond traditional measures such as BMI and waist circumference, which may fail to identify individuals at risk. This study develops and validates a novel metabolic risk classification system that incorporates body fat percentage (%BF), waist circumference (WC), and grip strength (GS) in Mexican adults. It aims to improve risk stratification and evaluate the association with metabolic syndrome. Methods: This cross-sectional study involved 300 young adults (18–22 years) from a university in Mexico City, utilizing body composition (%BF) and anthropometric measures (WC, GS) to categorize them into four risk groups: protective, low risk, increased risk, and high risk. A retrospective cohort of 166 adults (18–65 years) with complete clinical records was used for validation. Results: The inclusion of GS in the risk assessment significantly shifted the distribution in the young adult cohort, reducing the “no risk” category (15.5% males, 11.6% females) and expanding the higher-risk categories (70.2% males, 69% females). Metabolic parameters such as fasting glucose, triglycerides, HDL cholesterol, and blood pressure worsened progressively across the risk categories (p < 0.001). The high-risk group exhibited a markedly increased odds ratio for metabolic syndrome at 28.23 (10.83–73.6, p < 0.001), with no cases in the protective and low-risk groups. Conclusions: Integrating grip strength with %BF and WC into a risk classification system substantially enhances metabolic risk stratification, identifies at-risk individuals not previously detected, and confirms a protective group. This validated system provides a robust tool for early detection and targeted interventions, improving public health outcomes in metabolic health.
- 22 February 2025
- Published by MDPI AG in Journal of Functional Morphology and Kinesiology
- Vol. 10 (1) , 72
Open AccessA Novel Metabolic Risk Classification System Incorporating Body Fat, Waist Circumference, and Muscle Strength
Background: As metabolic diseases continue to rise globally, there is a growing need to improve risk assessment strategies beyond traditional measures such as BMI and waist circumference, which may fail to identify individuals at risk. This study develops and validates a novel metabolic risk classification system that incorporates body fat percentage (%BF), waist circumference (WC), and grip strength (GS) in Mexican adults. It aims to improve risk stratification and evaluate the association with metabolic syndrome. Methods: This cross-sectional study involved 300 young adults (18–22 years) from a university in Mexico City, utilizing body composition (%BF) and anthropometric measures (WC, GS) to categorize them into four risk groups: protective, low risk, increased risk, and high risk. A retrospective cohort of 166 adults (18–65 years) with complete clinical records was used for validation. Results: The inclusion of GS in the risk assessment significantly shifted the distribution in the young adult cohort, reducing the “no risk” category (15.5% males, 11.6% females) and expanding the higher-risk categories (70.2% males, 69% females). Metabolic parameters such as fasting glucose, triglycerides, HDL cholesterol, and blood pressure worsened progressively across the risk categories (p < 0.001). The high-risk group exhibited a markedly increased odds ratio for metabolic syndrome at 28.23 (10.83–73.6, p < 0.001), with no cases in the protective and low-risk groups. Conclusions: Integrating grip strength with %BF and WC into a risk classification system substantially enhances metabolic risk stratification, identifies at-risk individuals not previously detected, and confirms a protective group. This validated system provides a robust tool for early detection and targeted interventions, improving public health outcomes in metabolic health.